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Abstract 
Susceptibility to type 1 diabetes is strongly associated with HLA genes, implicating T cells in 
disease pathogenesis.  In humans, CD8 T cells predominantly infiltrate the islets, yet their 
activation and propagation likely requires CD4 T cell help. CD4 T cells can select from 
several differentiation fates following activation and this choice has profound consequences 
for their subsequent cytokine production and migratory potential. In turn, these features 
dictate which other immune cell types T cells interact with and influence, thereby determining 
downstream effector functions. Obtaining an accurate picture of the type of CD4 T cell 
differentiation associated with a particular immune-mediated disease therefore constitutes an 
important clue when planning intervention strategies. Early models of T cell differentiation 
focused on the dichotomy between T-helper 1 (Th1) and T-helper 2 (Th2) responses, with 
type 1 diabetes being mainly viewed as a Th1-mediated pathology. However several 
additional fate choices have emerged in recent years, including Th17 cells and follicular 
helper T cells. Here we revisit the issue of T cell differentiation in autoimmune diabetes, 
highlighting new evidence from both mouse models and patient samples.  We assess the 
strengths and the weaknesses of the Th1 paradigm, review the data on IL-17 production in 
type 1 diabetes and discuss emerging evidence for roles of IL-21 and follicular helper T cells 
in this disease setting. A better understanding of the phenotype of CD4 T cells in T1D will 
undoubtedly inform biomarker development, improve patient stratification and potentially 
reveal new targets for therapeutic intervention. 	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Multiple lines of evidence support key roles for both CD4 and CD8 T cells in the immune 
response that drives T1D.  The primary HLA associations with T1D are with the class II 
genes [1], the function of which is to activate CD4 T cells, and CD4 T cells are responsible 
for “licencing” CD8 T cell activation [2], making an understanding of the CD4 T cell 
compartment particularly relevant.  It has recently been shown that SNPs associated with type 
1 diabetes and other autoimmune diseases are preferentially enriched within CD4 T cell 
super-enhancers [3], a subset of transcriptional enhancers important for cell identity [4].  
Intriguingly, super-enhancer-associated genes show a striking enrichment for cytokines, 
cytokine receptors and factors that regulate T cell differentiation [3] suggesting control of T 
cell cytokine identity may be an important component of the genetic contribution to disease 
susceptibility.  Understanding CD4 T cell differentiation may therefore hold the key to 
understanding T1D disease mechanisms and ultimately developing new therapeutic 
interventions. 	  
The	  Th1	  paradigm	  in	  T1D	  
Evidence	  in	  favour	  of	  the	  Th1	  paradigm	  Early	  models	  of	  CD4	  T	  cell	  differentiation	  were	  based	  on	  a	  simple	  dichotomy	  between	  IFN-­‐γ-­‐dominated	  Th1	   responses	   and	   IL-­‐4-­‐dominated	  Th2	   responses.	   	   Th1	   cells	   can	  be	  induced	   by	   IL-­‐12	   and	   are	   important	   for	   macrophage	   activation	   and	   clearance	   of	  intracellular	  pathogens	  while	  Th2	  cells	  provide	  defense	  against	  helminth	  infection,	  and	  are	  associated	  with	  allergic	  disorders	  (e.g.	  asthma,	  rhinitis,	  eczema)	  involving	  IgE,	  mast	  cells	  and	  eosinophils.	  Viewed	   through	   this	   lens,	   autoimmune	  diabetes	  appeared	   to	   fall	  firmly	  into	  the	  Th1	  camp,	  with	  a	  seminal	  paper	  by	  Katz	  et	  al	  demonstrating	  that	  T	  cells	  expressing	   a	   diabetogenic	   TCR	   elicited	   diabetes	   in	   neonatal	   NOD	   mice	   when	  differentiated	  to	  a	  Th1,	  but	  not	  a	  Th2,	  phenotype	  [5]	  (Fig.	  1).	  Consistent	  with	  this	  idea,	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increasing	  levels	  of	  IFN-­‐γ	  were	  shown	  to	  correlate	  with	  progression	  to	  diabetes	  in	  NOD	  mice	  [6]	  and	  IFN-­‐γ	  was	  shown	  to	  be	  required	  for	  diabetes	  in	  a	  virus-­‐induced	  model	  [7].	  	  	  A	   cornerstone	  of	   the	  Th1/Th2	  dichotomy	   is	   the	   capacity	  of	   the	  products	  of	   one	  T	   cell	  subset	   to	   reciprocally	   inhibit	   the	   development	   of	   the	   other	   [8].	   In	   this	   respect,	  exogenous	   provision	   of	   IL-­‐4	   was	   shown	   to	   inhibit	   diabetes	   in	   NOD	   mice	   [9],	   and	  transgenic	   expression	   of	   IL-­‐4	   in	   the	   islets	   under	   the	   control	   of	   the	   insulin	   promoter	  completely	  prevented	  the	  development	  of	  diabetes	  [10].	  	  In	  addition,	  helminth	  infection,	  a	   strong	   driver	   of	   the	   Th2	   response,	   was	   shown	   to	   protect	   from	   diabetes	   in	   animal	  models	  [11].	  	  A	  number	  of	  studies	  pointed	  to	  a	  direct	  role	  for	  the	  Th1	  cell	  signature	  cytokine,	  IFN-­‐γ,	  in	  driving	  the	  disease	  process.	  Expression	  of	  IFN-­‐γ	  under	  the	  control	  of	  the	  human	  insulin	  promoter	  was	  shown	  to	  be	  sufficient	  to	  cause	  the	  development	  of	  diabetes	  in	  mice	  [12]	  and	  conversely	  blockade	  of	   IFN-­‐γ	   in	  NOD	  mice	   could	  prevent	  diabetes[13,	  14].	   	  There	  are	   a	  number	  of	  ways	   in	  which	   IFN-­‐γ	   could	  be	   envisaged	   to	   contribute	   to	   the	  disease	  process	   including	   by	   upregulating	   expression	   of	   MHC	   class	   I	   and	   II,	   facilitating	  macrophage	   activation,	   and	   increasing	   leukocyte	   extravasation	   by	   inducing	   adhesion	  molecules	   and	   chemokines	   (reviewed	   in	   [15]).	   Indeed	   IFN-­‐γ	   has	   been	   implicated	   in	  promoting	  the	  homing	  of	  diabetogenic	  T	  cells	  to	  the	  pancreatic	  islets	  in	  the	  NOD	  mouse	  [16].	   	   There	   is	   also	   a	   substantial	   literature	   directly	   implicating	   the	   IFN-­‐γ	   signaling	  pathway	   in	   beta	   cell	   death,	   the	   critical	   destructive	   event	   at	   the	   heart	   of	   autoimmune	  diabetes.	  IFN-­‐γ	  drives	  a	  persistent	  signal	  in	  pancreatic	  beta	  cells	  that	  can	  be	  inhibited	  by	  overexpression	  of	  suppressor	  of	  cytokine	  signaling-­‐1	  (SOCS1)[17]	  and	   islet	  expression	  of	   SOCS1	  was	   found	   to	   be	   protective	   in	   the	   RIP-­‐LCMV	  mouse	  model	   of	   diabetes	   [18].	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Both	  IFN-­‐γ-­‐/-­‐	  [16]	  and	  IFN-­‐γR-­‐/-­‐	  [19]	  islets	  are	  killed	  less	  effectively	  in	  vitro	  by	  CD8	  T	  cells	   [16]	   and	   cytokines	   [19].	   	   It	   is	   particularly	   striking	   that	   beta	   cells	   lacking	   IFN-­‐γR	  show	  reduced	  sensitivity	  not	   just	   to	   IFN-­‐γ	   induced	  death	  but	  also	   to	  TNF-­‐α	   and	   IL-­‐1β	  induced	  death	  [19],	  highlighting	  the	  capacity	  of	  IFN-­‐γ	  to	  sensitize	  beta	  cells	  to	  multiple	  potential	  death	  triggers.	  	  The	   balance	   between	   Th1	   and	   Th2	   responses	   has	   also	   been	   intensively	   studied	   in	  humans	  with	  T1D.	  Analysis	  of	  peripheral	  blood	  T	  cells	  from	  newly	  diagnosed	  adults	  (av.	  age	   ~29yr,	   av.	   disease	   duration	   ~5wk)	   provided	   support	   for	   an	   IFN-­‐γ–dominated	  response	   to	   islet	   autoantigens,	   revealing	   that	   the	   balance	   between	   IFN-­‐γ	   and	   IL-­‐10	  differed	  between	  patients	  and	  healthy	  controls.	   Individuals	  with	  T1D	  were	  more	  likely	  to	  have	  autoantigen-­‐specific	  T	  cells	  producing	  IFN-­‐γ	  alone,	  or	  to	  a	  lesser	  extent	  a	  mixed	  IFN-­‐γ	   and	   IL-­‐10	   repsonse,	  whereas	   nondiabetic	   subjects	   showed	   a	   clear	   bias	   towards	  production	  of	  IL-­‐10	  alone	  [20].	   	   	  Analogous	  results	  were	  obtained	  in	  a	  separate	  patient	  cohort	   with	   a	   similar	   demographic	   (average	   age	   28.5yr,	   average	   diabetes	   duration	   7	  months):	  interestingly	  first	  degree	  relatives	  also	  showed	  autoantigen	  specific	  responses	  that	  were	  characterised	  by	  more	  IFN-­‐γ	  and	  less	  IL-­‐10	  than	  healthy	  controls,	  although	  the	  ratios	  were	  not	  as	  skewed	  as	  in	  T1D	  patients	  [21].	  A	  study	  assessing	  mRNA	  expression	  in	  whole	   blood	   revealed	   levels	   of	   IFN-­‐γ	  mRNA	  were	   significantly	   higher	   in	   new	  onset	  T1D	   patients	   (av.	   age	   ~15yr,	   av.	   diabetes	   duration	   80	   days)	   compared	   with	   an	   age-­‐matched	   at	   risk	   cohort	   [22].	   This	   could	   potentially	   reflect	   a	   heightening	   of	   the	   Th1	  response	   during	   conversion	   to	   overt	   disease.	   Thus	   a	   considerable	   body	   of	   evidence	  supported	   the	   concept	   that	   an	   IFN-­‐γ	   producing	   T	   cell	   could	   be	   responsible	   for	   the	  pathogenic	  process	  in	  T1D	  (Fig.	  2A).	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Evidence	  against	  the	  Th1	  paradigm	  Although	   numerous	   studies	   support	   a	   Th1	   bias	   in	   T1D,	   not	   all	   evidence	   is	   consistent	  with	   this	   conclusion.	   	   Some	   studies	   using	   the	   NOD	   mouse	   concluded	   that	   beta	   cell	  destruction	   was	   a	   Th2-­‐mediated	   rather	   than	   Th1-­‐mediated	   event	   [23],	   while	   others	  concluded	   that	   both	   types	   of	   response	   were	   involved	   [24].	   	   At	   odds	   with	   data	   from	  short-­‐term	  Th2	   clones	   [5],	   long-­‐term	  cultured	  Th2	   clones	  derived	   from	   the	   same	  TCR	  transgenic	  animals	  did	  have	  the	  capacity	  to	  induce	  diabetes,	  and	  could	  even	  enhance	  the	  ability	  of	  Th1	  cells	  to	  cause	  disease	  [25].	  The	  effect	  of	  helminth	  products	  on	  the	  immune	  response	  was	  also	  shown	  to	  be	  more	  complex	  than	  originally	  anticipated,	  with	  effects	  on	  regulatory	   T	   cells	   and	   innate	   lymphoid	   cells	   [11],	   and	   it	   is	   now	   clear	   that	   helminth	  infection	  can	  protect	  from	  diabetes	  without	  necessarily	  invoking	  Th2	  differentiation	  [26,	  27].	  	  	  	  	  The	  finding	  that	  NOD	  mice	  deficient	  in	  IFN-­‐γRα	  exhibited	  striking	  resistance	  to	  diabetes	  [28]	  appeared	  to	  provide	  strong	  support	  for	  the	  Th1	  paradigm,	  however	  protection	  was	  subsequently	   attributed	   to	   a	   closely	   linked	   gene	   on	   chromosome	   10	   that	  was	   carried	  over	  from	  the	  129	  background	  [29,	  30].	  	  In	  fact,	  deficiency	  in	  IFN-­‐γ	  [31]	  or	  the	  β	  chain	  of	  its	   receptor	   [30]	   surprisingly	   leads	   to	   only	   a	   mild	   delay	   in	   diabetes	   development.	  	  Deficiency	   of	   IL-­‐4	   failed	   to	   exacerbate	   disease	   in	   NOD	   mice	   [32]	   while	   injection	   of	  recombinant	  IFN-­‐γ	  did	  not	  accelerate	  diabetes	  [33]	  and	  indeed	  could	  even	  inhibit	  it	  [34].	  In	  certain	  experimental	  settings,	  the	  regulatory	  T	  cells	  protecting	  from	  diabetes	  actually	  required	  IFN-­‐γ	  [35].	  	  Perhaps	  most	  surprising	  was	  the	  revelation	  that	  the	  ability	  of	  CFA	  to	   protect	   NOD	   mice	   from	   diabetes,	   traditionally	   assumed	   to	   reflect	   IL-­‐4	   or	   IL-­‐10	  production,	  was	  largely	  dependent	  on	  IFN-­‐γ	  [36].	  	  Collectively	  these	  data	  questioned	  the	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traditional	  view	  that	  diabetes	  was	  caused	  by	  Th1	  cells	  making	  IFN-­‐γ	  and	  suggested	  the	  situation	  might	  be	  rather	  more	  complex.	  	  Data	  deriving	   from	  analysis	   of	  patient	   samples	   is	   also	  not	   clear-­‐cut.	   Insulin-­‐reactive	  T	  cells	  cloned	  from	  the	  pancreatic	  lymph	  nodes	  of	  individuals	  with	  long-­‐standing	  diabetes	  expressed	   IL-­‐13	   but	   not	   IFN-­‐γ	   in	   response	   to	   stimulation	   [37].	   In	   individuals	   newly	  diagnosed	  with	  T1D	  some	  reports	  suggested	  IFN-­‐γ	  production	  to	  be	  lower	  [38,	  39]	  while	  other	   suggested	   an	   initial	   increase	   in	   IFN-­‐γ	   in	   the	   early	   weeks	   following	   diagnosis	  followed	  by	  a	  subsequent	  decrease	  [22,	  40].	  In	  an	  analysis	  of	  serum	  cytokine	  levels	  in	  44	  newly	   diabetic	   children	   compared	   with	   22	   age-­‐matched	   controls,	   although	   Th1-­‐associated	   products	   such	   as	   RANTES	   and	  MIP-­‐1α	   were	   elevated,	   so	   too	   were	   factors	  considered	  indicative	  of	  a	  Th2	  response	  such	  as	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐10	  [41].	  Likewise,	  the	  increase	   in	   IFN-­‐γ	   mRNA	   detected	   in	   whole	   blood	   from	   newly	   diabetic	   individuals	  compared	  with	  at	  risk	  individuals	  was	  mimicked	  by	  a	  similar	  increase	  in	  IL-­‐4	  and	  IL-­‐10	  [22].	   	   A	   separate	   analysis	   concluded	   that	   T	   cells	   from	   people	   with	   type	   1	   diabetes	  produced	  equivalent	  amounts	  of	  IFN-­‐γ	  and	  IL-­‐13	  in	  response	  to	  autoantigens	  as	  T	  cells	  from	   control	   subjects	   [42].	   Regarding	   the	   prediabetic	   period,	   the	   Th1	   response	   to	  autoantigen	   has	   been	   reported	   to	   be	   increased	   in	   one	   study	   [43]	   and	   decreased	   in	  another	  [44]	  in	  at	  risk	  individuals.	  One	  must	  be	  mindful	  when	  assaying	  peripheral	  blood	  that	  a	  lower	  response	  could	  potentially	  signify	  the	  migration	  of	  disease-­‐relevant	  T	  cells	  to	   the	   pancreas.	   	  Notwithstanding	   this	   consideration,	   it	   is	   clear	   that	   not	   all	   data	   from	  mouse	   models	   and	   patients	   provide	   consistent	   support	   for	   the	   dominance	   of	   a	   Th1	  response	  in	  type	  1	  diabetes.	  	  	  
The	  Th17	  revision	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Th17	  cells	  in	  mouse	  models	  of	  autoimmune	  diabetes	  The	   emergence	   of	   Th17	   cells	   [45,	   46]	   provided	   a	   major	   revision	   of	   the	   Th1/Th2	  paradigm	   [47]	   and	   raised	   the	   possibility	   that	   tissue-­‐specific	   autoimmunity	   might	   be	  driven	  by	  IL-­‐17	  producing	  T	  cells	  rather	  than	  Th1	  cells.	  	  However	  the	  role	  of	  Th17	  cells	  in	   diabetes	   remains	   far	   from	   clear.	   	   In	   mice,	   early	   work	   implicated	   IL-­‐17	   in	   the	  pathogenic	   process	   [48,	   49]	   however	   it	   was	   subsequently	   shown	   that	   silencing	   IL-­‐17	  expression	  did	  not	  protect	  NOD	  mice	  from	  diabetes	  [50].	  	  Furthermore,	  there	  were	  even	  suggestions	  that	  IL-­‐17	  could	  protect	  from	  diabetes.	  	  Kriegel	  et	  al	  [51]	  took	  advantage	  of	  the	   fact	   that	   colonization	   of	   the	   gastrointestinal	   tract	   with	   segmented	   filamentous	  bacteria	  (SFB)	  is	  known	  to	  cause	  Th17	  induction	  [52]	  and	  asked	  whether	  SFB-­‐colonised	  NOD	  mice	  developed	  diabetes	  with	  different	  kinetics	  to	  their	  SFB-­‐negative	  counterparts.	  	  Strikingly	  the	  presence	  of	  SFB	  appeared	  to	  delay	  diabetes	  with	  only	  16%	  of	  SFB+	  mice	  developing	   diabetes	   by	   30	   weeks	   compared	   with	   91%	   of	   SFB-­‐	   animals.	   As	   expected	  Th17	   signature	  genes	  were	   strongly	  upregulated	   in	  SFB+	  animals	  whereas	   transcripts	  associated	  with	  Th1,	  Th2	  and	  Treg	  cells	  were	  unchanged	   [51].	   	  These	  data	  are	   clearly	  more	  consistent	  with	  a	  role	  for	  IL-­‐17,	  or	  other	  Th17	  cell	  products,	  in	  delaying	  rather	  that	  promoting	   diabetes	   development.	   A	   similar	   conclusion	   emerged	   from	   studies	   in	   the	  diabetes-­‐prone	  Bio-­‐Breeding	  (BB)	  rat	  in	  which	  oral	  transfer	  of	  a	  particular	  Lactobacillus	  strain	   promoted	   Th17	   differentation	   and	   protected	   from	   diabetes	   [53].	   Furthermore,	  injection	   of	   Th17	   polarised	   cells	   from	   CFA-­‐injected	   NOD	   mice	   delayed	   diabetes	   in	  NOD/SCID	  recipients	  in	  a	  manner	  that	  depended,	  at	  least	  in	  part,	  on	  IL-­‐17	  [54].	  	  	  The	   role	   of	   Th17	   cells	   in	   diabetes	   has	   also	   been	   addressed	   using	   adoptive	   transfer	   of	  TCR	   transgenic	   T	   cells	   specific	   for	   pancreatic	   antigen.	   Highly	   purified	   Th17-­‐polarised	  BDC2.5	  T	  cells	  were	  capable	  of	  inducing	  diabetes	  but	  appeared	  to	  achieve	  this	  by	  further	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differentiating	   to	   a	   Th1	   phenotype	   [55,	   56].	   Indeed	   the	   ensuing	   disease	   could	   be	  inhibited	  by	  antibodies	  to	  IFN-­‐γ	  but	  not	  IL-­‐17	  [55,	  56].	  	  On	  the	  other	  hand,	  two	  reports	  documented	  the	  ability	  of	  IFN-­‐γ-­‐/-­‐	  Th17	  cells	  to	  successfully	  transfer	  diabetes	  [57,	  58]	  arguing	  against	  a	  requirement	  for	  a	  Th1	  transition.	  Interestingly,	  if	  T	  cells	  expressing	  a	  different	   pancreatic	   antigen-­‐specific	   TCR	   (BDC6.9)	   are	   used	   far	   less	   Th17	   to	   Th1	  conversion	  is	  observed	  yet	  diabetes	  is	  still	   induced	  [58].	   	  Thus,	   individual	  T	  cell	  clones	  may	  differ	  in	  the	  cytokines	  they	  use	  to	  elicit	  disease,	  perhaps	  depending	  on	  the	  affinity	  of	  their	  TCR-­‐antigen	  interactions.	  	  Taken	  together,	  the	  murine	  studies	  to	  date	  suggest	  that	  although	  IL-­‐17	  is	  upregulated	  in	  the	  early	  stages	  of	  diabetes	  development	  [58,	  59]	  it	  does	  not	  necessarily	  follow	  that	  this	  cytokine,	  or	  indeed	  the	  Th17	  subset,	  is	  necessary	  for	  disease.	  	  
Th17	  cells	  in	  humans	  with	  type	  1	  diabetes	  Several	   studies	   have	   indicated	   an	   increase	   in	   T	   cell	   IL-­‐17	   production	   in	   humans	  with	  T1D,	   especially	   in	   the	   very	   early	   stages	   of	   disease.	   Children	   with	   new	   onset	   and	  longstanding	  T1D	  (mean	  age	  8.7	  years)	  were	  shown	  to	  have	  more	  IL-­‐17-­‐positive	  T	  cells	  compared	  with	   age-­‐matched	  non-­‐diabetic	   controls	   [60].	   	   In	   a	   separate	   study,	   children	  within	  6	  months	  of	  T1D	  diagnosis	  (mean	  age	  9.6	  years)	  were	  shown	  to	  exhibit	  increased	  IL-­‐17	  secretion	   from	  both	  CD4	  and	  CD8	  T	  cells	   [61].	  Both	   IL-­‐6	  and	   IL-­‐1β	   can	  promote	  Th17	   development	   [62,	   63]	   so	   the	   demonstration	   that	   monocytes	   from	   T1D	   patients	  expressed	  elevated	  levels	  of	  mRNA	  for	  IL-­‐6	  and	  IL-­‐1β	  provided	  a	  potential	  explanation	  for	   increased	   IL-­‐17	  production	   [64].	   	  However	   this	  has	  not	  been	  universally	  observed	  [60]	   and	  may	   depend	   on	   the	   demographic	   of	   the	   cohort.	   A	   separate	   analysis	   of	   first-­‐degree	   relatives	   of	   T1D	   patients	   showed	   that	   monocytes	   from	   those	   that	   were	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autoantibody	   positive	   produced	  more	   IL-­‐1β	   and	   less	   IL-­‐6	   in	   response	   to	   TLR	   ligation	  compared	   with	   those	   from	   seronegative	   individuals.	   IL-­‐1β	   plays	   multiple	   roles	   in	  autoimmune	   islet	   infiltration	   and	   in	   addition	   to	   promoting	   IL-­‐17	   production	   can	   also	  directly	  modify	  beta	  cell	  survival	  and	  function	  [65].	  	  A	  key	  challenge	  associated	  with	  studying	  T	  cell	  differentiation	  in	  diabetes	  patients	  is	  the	  limitation	   of	   focusing	   only	   on	   peripheral	   blood	   samples.	   	   In	   an	   impressive	   attempt	   to	  circumvent	   this	   problem,	   Ferraro	   and	   colleagues	   studied	   T	   cells	   isolated	   from	   the	  pancreatic	   lymph	   nodes	   of	   T1D	   patients	   undergoing	   pancreas	   or	   pancreas/kidney	  transplant.	   These	   were	   compared	   with	   pancreatic	   lymph	   nodes	   from	   nondiabetic	  donors.	  	  Careful	  analysis	  of	  T	  cell	  cytokine	  production,	  and	  chemokine	  receptor	  profiles,	  established	   that	   the	   pancreatic	   lymph	   nodes	   of	   type	   1	   diabetic	   subjects	   had	   a	   higher	  frequency	  of	  Th17	  cells	  [66].	  	  More	  recently	  an	  increase	  in	  the	  frequency	  of	  IL-­‐17+	  cells	  was	  found	  in	  the	  peripheral	  blood	  of	  adult	  T1D	  patients	  when	  gating	  on	  CD45RA-­‐CCR6+	  population	  of	  CD4	  T	  cells[67].	  Thus	  several	  lines	  of	  evidence	  point	  to	  an	  increase	  in	  IL-­‐17	  production	  in	  the	  T1D	  setting.	  	  
Possible	  role	  for	  Th1/17	  cells	  in	  type	  1	  diabetes?	  One	  area	  worthy	  of	  note	  in	  considering	  the	  contribution	  of	  Th17	  cells	  to	  T1D	  is	  the	  role	  of	  cells	  with	  a	  propensity	  to	  make	  both	  IL-­‐17	  and	  IFN-­‐γ	  (sometimes	  called	  Th1/17	  cells).	  	  Cells	  co-­‐producing	  IL-­‐17	  and	  IFN-­‐γ	  were	  originally	  identified	  in	  the	  gut	  of	  patients	  with	  Crohn’s	  Disease	  [68]	  and	  were	  subsequently	  shown	  to	  be	  present	  in	  the	  mouse	  colon	  in	  an	  adoptive	  transfer	  model	  of	  intestinal	  inflammation	  [69].	   	  Fate	  mapping	  experiments	  in	  mice	  established	  that	  in	  autoimmune	  settings,	  IL-­‐17-­‐positive	  T	  cells	  can	  initiate	  IFN-­‐γ	  production	  leading	  to	  the	  presence	  of	  a	  substantial	  number	  of	  T	  cells	  co-­‐expressing	  both	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cytokines	   [70].	  A	   closer	   analysis	   of	   the	   literature	   reveals	   hints	   that	   cells	   co-­‐producing	  IFN-­‐γ	  and	  IL-­‐17	  may	  be	  present	  in	  the	  T1D	  setting	  too.	  	  By	  measuring	  IFN-­‐γ	  transcripts	  within	   sorted	   IL-­‐17-­‐producing	   cells,	   Reinert-­‐Hartwall	   et	   al	   [71]	   found	   an	   increased	  propensity	   of	   IL-­‐17+	   cells	   to	   make	   IFN-­‐γ	   in	   children	   with	   T1D	   (mean	   age	   8.3	   years)	  compared	  with	  healthy	  controls.	  	  Interestingly	  this	  phenomenon	  was	  even	  more	  striking	  in	   children	   who	   had	   not	   developed	   diabetes	   but	   exhibited	   advanced	   beta	   cell	  autoimmunity	   and	   impaired	   glucose	   tolerance	   (mean	   age	   7.7	   years)	   [71].	   	   Consistent	  with	   this	   theme,	   a	   separate	   study	  of	   IL-­‐17	  production	   in	   the	  T1D	  setting	   found	   that	  T	  cells	  co-­‐producing	  IL-­‐17	  and	  IFN-­‐γ	  were	  present	  in	  4	  out	  of	  11	  of	  the	  diabetic	  children	  examined	   [60].	   	   In	   addition,	   when	   T	   cells	   from	   human	   pancreatic	   lymph	   nodes	   were	  examined,	   there	   was	   a	   suggestion	   that	   IFN-­‐γ	   as	   well	   as	   IL-­‐17	   expression	   was	  upregulated	   in	   those	   deriving	   from	   T1D	   patients,	   although	   the	   results	   did	   not	   reach	  statistical	  significance	  [66].	  Finally,	  both	  IL-­‐17	  and	  IFN-­‐γ	  were	  upregulated	  at	  the	  mRNA	  level	   within	   the	   pancreatic	   islets	   of	   an	   individual	   who	   died	   within	   5	   days	   of	   T1D	  diagnosis	   [72].	   	   Thus,	   the	   presence	   of	   T	   cells	   that	   co-­‐produce	   IL-­‐17	   and	   IFN-­‐γ	   could	  potentially	   be	   a	   feature	   of	   T1D	   and	   this	   area	  may	  warrant	   further	   investigation	   (Fig.	  
2B).	  
	  
IL-­‐21	  production	  in	  Type	  1	  Diabetes	  
IL-­‐21	  is	  required	  for	  autoimmune	  diabetes	  in	  mice	  	  IL-­‐21	   is	   familiar	   to	   the	   diabetes	   community	   as	   a	   candidate	   gene	   at	   the	   diabetes	  susceptibility	  locus	  Idd3	  [73-­‐75],	  and	  levels	  of	  IL-­‐21	  mRNA	  have	  been	  shown	  to	  increase	  during	   diabetes	   development	   in	   mice	   [76-­‐78]	   (Table	   1).	   	   IL-­‐21	   is	   a	   member	   of	   the	  common-­‐γ	  chain	  receptor	  family	  of	  cytokines	  that	   includes	  IL-­‐2,	  IL-­‐4,	  IL-­‐7,	  IL-­‐9	  and	  IL-­‐15.	   	   Its	   receptor	   is	   a	   heterodimer,	   comprising	   the	   common	   γ-­‐chain	   and	   an	   IL-­‐21Rα	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subunit,	  which	   is	   broadly	   expressed	   on	   a	  wide	   range	   of	   haematopoietic	   cell	   types.	   	   It	  came	   as	   something	   of	   a	   surprise	  when	   two	   groups	   reported	   that	   IL-­‐21	   signaling	  was	  critically	  required	  for	  diabetes	  in	  NOD	  mice	  [78,	  79].	  	  In	  one	  report	  less	  than	  10%	  of	  IL-­‐21R-­‐/-­‐	  NOD	  had	  developed	  diabetes	  by	  35	  weeks	  [79]	  while	  in	  the	  other	  none	  of	  the	  IL-­‐21R-­‐/-­‐	  NOD	  animals	  were	  diabetic	  even	  at	  60	  weeks	  of	  age,	  a	  timepoint	  at	  which	  >90%	  of	  IL-­‐21R	  sufficient	  animals	  had	  developed	  disease	  [78].	  	  	  The	  timing	  of	   these	  reports	  coincided	  with	  the	  discovery	  that	   IL-­‐21	  can	  enhance	  Th17	  differentiation	  and	  can	  itself	  be	  produced	  by	  Th17	  cells	  to	  exert	  feedback	  in	  an	  autocrine	  fashion	  [80-­‐82].	  	  This	  prompted	  the	  question	  of	  whether	  a	  defect	  in	  Th17	  differentiation	  might	  underlie	   the	   lack	  of	  diabetes	   in	   IL-­‐21R-­‐/-­‐	  mice.	   	  Support	   for	  such	  a	  notion	  came	  from	  the	  observation	  that	  decreased	  numbers	  of	  IL-­‐17-­‐producing	  T	  cells	  were	  detected	  in	  IL-­‐21R	  -­‐/-­‐	  mice	  in	  one	  study	  [79].	  However	  in	  the	  other	  study	  [78],	  IL-­‐17	  producing	  T	  cells	  were	   slightly	   increased,	   and	   the	  amount	  of	   IL-­‐17	   following	   in	  vitro	   restimulation	  was	   actually	   slightly	   higher	   in	   IL-­‐21R-­‐/-­‐	   mice,	   arguing	   against	   a	   reduction	   in	   IL-­‐17	  production	  being	  responsible	  for	  disease	  protection.	  	  	  Therefore	  the	  role	  of	  IL-­‐21	  in	  the	  development	   of	   diabetes	   appeared	   to	   be	   more	   than	   just	   an	   effect	   on	   Th17	  differentiation.	  	  
Possible	  roles	  for	  IL-­‐21	  in	  autoimmune	  diabetes	  So	   if	   IL-­‐21	   did	   not	   exert	   its	   pro-­‐diabetogenic	   effects	   by	   IL-­‐17	   upregulation,	   how	   else	  could	  its	  ability	  to	  promote	  disease	  be	  explained?	  The	  answer	  to	  this	  critical	  question	  is	  not	  yet	  fully	  elucidated.	  It	  seems	  unlikely	  that	  IL-­‐21	  acts	  directly	  on	  pancreatic	  beta	  cells	  since	  they	  appear	  to	  lack	  expression	  of	  the	  IL-­‐21	  receptor	  [78].	  However,	  the	  presence	  of	  IL-­‐21	   local	   to	   beta	   cells	   is	   sufficient	   to	   trigger	   the	   cascade	   necessary	   for	   diabetes	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induction,	  even	  in	  non-­‐autoimmune	  prone	  C57BL/6	  mice	  [78].	  	  Accordingly,	  expression	  of	   IL-­‐21	  under	   the	  human	   insulin	  promoter	  elicited	   spontaneous	  diabetes	   in	  ~80%	  of	  mice,	  with	  substantial	  islet	  infiltration	  by	  CD4	  T	  cells	  and	  macrophages	  as	  well	  as	  DC	  and	  B	   cells	   [78].	   Forced	   expression	   of	   IL-­‐21	   was	   therefore	   sufficient	   to	   trigger	   islet	  infiltration	   –	   but	   is	   IL-­‐21	   required	   for	   spontaneous	   islet	   infiltration	   occurring	   in	   the	  absence	   of	   transgenic	   overexpression?	   	   The	   answer	   appears	   to	   be	   yes	   since	   mice	  deficient	   in	   IL-­‐21	   signaling	   were	   virtually	   devoid	   of	   inflammatory	   infiltration	   in	   the	  islets	   [78,	   79].	   	   Furthermore,	   short-­‐term	   blockade	   of	   the	   IL-­‐21	   pathway	   appeared	   to	  reverse	  established	  insulitis	  in	  NOD	  mice,	  resulting	  in	  a	  significantly	  reduced	  numbers	  of	  lymphocytes	  with	  the	  islet	  lesion	  [83].	  	  Which	   cell	   is	   the	   key	   target	   for	   the	   pro-­‐diabetogenic	   effects	   of	   IL-­‐21?	   	   IL-­‐21	   is	   an	  extraordinarily	   pleiotropic	   cytokine	   with	   the	   capacity	   to	   act	   on	   a	   broad	   array	   of	   cell	  types	  including	  CD4	  and	  CD8	  T	  cells,	  NK	  cells,	  B	  cells,	  macrophages	  and	  DC	  (Fig.	  3).	  In	  this	  respect,	  McGuire	  et	  al	  [84]	  found	  that	  when	  diabetes	  was	  induced	  in	  NOD/SCID	  mice	  by	  adoptive	  transfer	  of	  CD4	  and	  CD8	  T	  cells,	  it	  was	  the	  CD8	  T	  cells	  that	  required	  IL-­‐21R	  in	  order	  for	  diabetes	  to	  develop.	  	  Loss	  of	  IL-­‐21	  sensitivity	  in	  the	  CD4	  compartment	  led	  to	  only	  a	  partial	  reduction	  in	  diabetes	  incidence.	  	  In	  contrast,	  a	  similar	  experiment	  by	  Van	  Belle	  et	  al	  [85]	  concluded	  that	  CD4	  T	  cells	  were	  the	  obligate	  targets	  of	  IL-­‐21,	  with	  IL-­‐21	  responsiveness	   in	   CD8	   T	   cells	   having	   only	   a	   partial	   affect.	   	   While	   at	   first	   sight	   these	  findings	  are	  hard	  to	  reconcile,	  it	  is	  probably	  reasonable	  to	  conclude	  that	  IL-­‐21	  can	  act	  on	  both	  CD4	  and	  CD8	  T	  cells	  to	  promote	  diabetes,	  with	  the	  relative	  importance	  of	  each	  axis	  being	  dependent	  on	  the	  precise	  experimental	  context.	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Effects	   of	   IL-­‐21	   on	   the	   CD4	   compartment	   include	   the	   promotion	   of	   cell	   survival,	   as	  illustrated	   by	   the	   increased	   sensitivity	   of	   IL-­‐21R-­‐/-­‐	   T	   cells	   to	   activation	   induced	   cell	  death	   [85].	   In	   addition,	   IL-­‐21	   may	   act	   on	   macrophages,	   increasing	   their	   capacity	   to	  stimulate	  CD4	  T	  cell	  proliferation	  [86].	  	  A	  further	  manner	  in	  which	  IL-­‐21	  may	  contribute	  to	  autoimmunity	   is	  by	   imparting	  resistance	  to	  Treg	  suppression.	   	  Several	   investigators	  have	  shown	  that	  IL-­‐21	  is	  able	  to	  counteract	  the	  suppressive	  function	  of	  Treg	  [77,	  87]	  and	  that	  this	  requires	  the	  IL-­‐21	  to	  act	  on	  conventional	  CD4	  T	  cells	  [85,	  88]	  rather	  than	  the	  Treg	  themselves.	  	  Interestingly	  resistance	  to	  Treg	  suppression	  has	  been	  reported	  in	  both	  mice	   [77]	   and	   humans	   with	   type	   1	   diabetes	   [89,	   90]	   although	  many	   other	   factors	   in	  addition	  to	  IL-­‐21	  are	  likely	  to	  contribute	  to	  this	  effect	  [91].	  	  IL-­‐21	  is	  also	  known	  to	  play	  key	  roles	  in	  orchestrating	  T	  cell:B	  cell	  interactions	  and	  this	  may	   be	   relevant	   in	   the	   light	   of	   the	   possible	   contribution	   of	   B	   cells	   to	   diabetes	  pathogenesis	  [92-­‐94].	   	   IL-­‐21	  can	  promote	  the	  formation	  of	  antibody-­‐producing	  plasma	  cells	  [95,	  96],	  and	  can	  also	  instruct	  germinal	  center	  B	  cell	  development	  by	  upregulating	  expression	  of	  the	  transcription	  factor	  Bcl6	  [97,	  98].	  	  It	  was	  recently	  shown	  that	  IL-­‐21	  can	  upregulate	  B	  cell	  CD86	  expression	  [99]	  which	  in	  turn	  can	  influence	  the	  homeostasis	  of	  follicular	  helper	  T	  cells	  (TFH)	  [100]	  (see	  below)	  and	  facilitate	  further	  B	  cell	  stimulation.	  	  IL-­‐21	  could	  therefore	  conceivably	  contribute	  to	  diabetes	  development	  by	  acting	  on	  the	  B	  cell	  compartment.	  	  Interestingly	  recent	  data	  suggest	  that	  an	  alteration	  at	  the	  IL-­‐2/IL-­‐21	  locus	  that	  confers	  increased	  risk	  for	  T1D	  is	  associated	  with	  decreased	  production	  of	  IL-­‐10	   in	   memory	   B	   cells	   [101].	   Thus	   there	   are	   likely	   to	   be	   additional	   IL-­‐21-­‐dependent	  control	  points	  relevant	  to	  diabetes	  pathogenesis	  that	  are	  not	  yet	  fully	  elucidated.	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In	   an	   interesting	  development,	   it	   has	   also	  been	   shown	   that	   IL-­‐21	   can	   act	   on	  dendritic	  cells	   to	   influence	   their	  maturation	   and	  migration.	   	   In	   a	   virus-­‐induced	   diabetes	  model,	  pancreatic	  DCs	  required	  IL-­‐21R	  signals	  to	  acquire	  CCR7	  and	  MHC	  class	  II	  and	  migrate	  to	  the	   draining	   lymph	   node	   [85].	   	   Indeed	   disease	   resistance	   associated	   with	   IL-­‐21R	  deficiency	  could	  be	  overcome	  by	  the	  adoptive	  transfer	  of	  IL-­‐21R	  sufficient	  DC	  [85].	  This	  contrasts	  with	  the	  capacity	  of	  IL-­‐21	  to	  inhibit	  DC	  maturation	  in	  vitro	  [102],	  and	  suggests	  that	  its	  effects	  may	  be	  highly	  context	  dependent.	  	  In	  this	  regard,	  it	  has	  emerged	  that	  IL-­‐21	  is	  a	  potent	  inducer	  of	  DC	  apoptosis,	  an	  effect	  that	  is	  reversed	  in	  the	  presence	  of	  GM-­‐CSF	  [103].	  	  	  This	  is	  reminiscent	  of	  the	  situation	  in	  B	  cells	  where	  IL-­‐21	  can	  induce	  either	  activation	   or	   apoptosis	   depending	   on	   the	   context	   [104,	   105],	   and	   suggests	   that	   the	  capacity	  of	  IL-­‐21	  to	  influence	  DC	  biology	  may	  be	  far	  greater	  that	  previously	  appreciated.	  	  	  
IL-­‐21	  in	  human	  T1D	  It	  has	  recently	  been	  found	  that	  CD4	  T	  cells	  from	  T1D	  patients	  produce	  higher	  levels	  of	  IL-­‐21	  in	  response	  to	  in	  vitro	  restimulation	  than	  T	  cells	  from	  non-­‐diabetic	  individuals	  [67,	  106].	  Work	  by	  Kenefeck	  et	  al	  [106]	   focused	  on	   adult	   patients,	  with	   a	  mean	   age	  of	   37,	  while	   analysis	   by	  Ferreira	   and	   colleagues	   [67]	   also	   included	   children	   (median	   age	  14,	  range	  6-­‐42yr).	   	   Importantly,	  both	  studies	  normalized	  their	  analysis	  to	  the	  memory	  cell	  population	  to	  avoid	  variation	  in	  the	  frequency	  of	  memory	  T	  cells	  affecting	  their	  results.	  	  Interestingly	   the	   IL-­‐21-­‐producing	   T	   cells	   in	   T1D	   patients	   co-­‐expressed	   high	   levels	   of	  IFN-­‐γ	  and	  TNF-­‐α [106]	  (Fig.	  2C).	  	  T	  cells	  co-­‐expressing	  IL-­‐21,	  IFN-­‐γ	  and	  TNF-­‐α	  were	  also	  detected	  infiltrating	  the	  pancreas	  in	  a	  TCR	  transgenic	  mouse	  model	  of	  diabetes	  [106].	  	  In	  a	  separate	  study,	  mRNA	  levels	  of	   IL-­‐21	  were	  found	  to	  be	  higher	   in	  total	  CD4	  T	  cells	  from	  T1D	  patients	  [107],	  although	  Kenefeck	  et	  al	  found	  no	  significant	  difference	  in	  IL-­‐21	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mRNA	  levels,	  even	  when	  homing	  in	  on	  the	  memory	  T	  cell	  population	  [106].	  It	  is	  possible	  that	  IL-­‐21	  production	  is	  more	  pronounced	  at	  the	  earlier	  disease	  stages	  since	  the	  former	  study	  [107]	  examined	  individuals	  within	  2	  years	  of	  onset	  while	  most	  participants	  in	  the	  latter	  study	  [106]	  were	  long-­‐standing	  diabetes	  patients.	  In	  all	  3	  studies,	  the	  increase	  in	  IL-­‐21	   was	   observed	   in	   bulk	   CD4	   T	   cells	   and	   the	   authors	   did	   not	   attempt	   to	   identify	  autoantigen-­‐specific	  cells.	  The	  changes	  in	  IL-­‐17	  expression	  in	  T1D	  discussed	  earlier	  [60,	  66,	  71]	  were	  also	  detected	  in	  polyclonal	  T	  cell	  populations.	  Conceivably,	  the	  factors	  that	  influence	  the	  propensity	  of	  T	  cells	  to	  produce	  a	  particular	  cytokine	  may	  act	  on	  all	  CD4	  T	  cells,	  rather	  than	  solely	  those	  responding	  to	  islet	  antigens,	  however	  this	  issue	  warrants	  further	  investigation.	  	  	  Taken	  together,	  analysis	  of	  mouse	  models	  has	  clearly	  demonstrated	  that	  the	  loss	  of	  IL-­‐21	   signaling	   inhibits	   diabetes	   development	   while	   conversely	   its	   local	   production	   is	  sufficient	  to	  initiate	  immune-­‐mediated	  islet	  destruction.	  	  The	  overproduction	  of	  IL-­‐21	  in	  T1D	   patients	   highlights	   this	   cytokine	   as	   worthy	   of	   further	   investigation	   in	   respect	   of	  disease	  pathogenesis	  in	  humans.	  	  
Follicular	  Helper	  T	  cells	  in	  Type	  1	  Diabetes	  
Expansion	  of	  TFH	  in	  mice	  and	  humans	  with	  autoimmune	  diabetes	  Given	   the	   link	   between	   IL-­‐21	   production	   and	   diabetes	   pathogenesis,	   a	   key	   question	  becomes	  what	  is	  the	  identity	  of	  the	  IL-­‐21-­‐producing	  cell?	  	  IL-­‐21	  is	  the	  signature	  cytokine	  for	  follicular	  helper	  T	  cells	  (TFH),	  the	  subset	  that	  specializes	  in	  providing	  help	  for	  B	  cell	  antibody	  production	  [108,	  109].	  In	  this	  regard,	  a	  recent	  unbiased	  microarray	  analysis	  of	  T	   cells	   responding	   to	   islet	   antigen	   in	   the	   pancreatic	   lymph	   node	   of	   mice	   revealed	   a	  striking	  signature	  of	  TFH	  differentiation	  [106].	  	  The	  top	  20	  most	  significantly	  upregulated	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genes	  in	  T	  cells	  responding	  to	  islet	  antigen	  included	  4	  archetypal	  TFH	  genes	  (CXCR5,	  PD-­‐1,	   IL-­‐21,	   Bcl6)	   and	   flow	   cytometry	   analysis	   demonstrated	   that	   T	   cells	   with	   a	   TFH	  phenotype	  were	  overrepresented	  in	  the	  pancreatic	  lymph	  nodes	  [106].	  	  Follicular	  helper	  T	   cells	   are	   so-­‐named	   due	   to	   their	   capacity	   to	   enter	   the	   B	   cell	   follicles	   of	   secondary	  lymphoid	   tissues	   where	   they	   initiate	   the	   formation	   of	   germinal	   centers.	   	   These	   are	  specialized	   structures	   where	   B	   cells	   mutate	   their	   immunoglobulin	   molecules	   so	   that	  those	  with	  higher	  affinity	  for	  antigen	  can	  be	  selected	  to	  enter	  the	  long-­‐lived	  plasma	  cell	  and	   memory	   B	   cell	   pools.	   The	   capacity	   of	   B	   cells	   to	   solicit	   help	   from	   TFH	   within	   the	  germinal	  center	  is	  a	  key	  factor	  in	  the	  selection	  procedure.	  	  Importantly	  germinal	  centers	  could	   be	   demonstrated	   in	   the	   pancreatic	   LN	   of	   diabetic	  mice	   by	   confocal	  microscopy	  [106],	  consistent	  with	  the	  presence	  of	  a	  functional	  TFH	  population.	  	  The	   finding	   that	  diabetes	  was	  associated	  with	  TFH	  differentiation	   in	  mice	  prompted	  an	  analysis	  of	  TFH	  cells	   in	   the	  peripheral	  blood	  of	  humans	  with	  T1D.	   	  Within	   the	  memory	  pool,	   the	  %	  CXCR5+	   and	  CXCR5+ICOS+	  T	   cells	  was	   found	   to	   be	   significantly	   higher	   in	  individuals	  with	  T1D	  [106].	  	  Consistent	  with	  this,	  an	  increase	  in	  peripheral	  blood	  T	  cells	  with	  a	  TFH	  phenotype	  has	  also	  been	  reported	  in	  2	  independent	  cohorts	  of	  T1D	  patients,	  one	  of	  which	  comprised	  exclusively	  new	  onset	  patients	  (within	  2yr	  diagnosis,	  mean	  age	  23)	   [107]	  while	   the	   other	   included	   individuals	  with	   disease	   duration	   ranging	   from	  2-­‐20yr	  (median	  age	  32)	  [67].	  	  Thus	  in	  both	  mouse	  models	  and	  in	  humans,	  an	  expansion	  of	  cells	  with	  a	  TFH	  phenotype	  appears	  to	  be	  a	   feature	  of	  autoimmune	  diabetes	  (Table	  2).	  Regarding	   the	   issue	   of	  whether	   TFH	  might	   represent	   the	   source	   of	   IL-­‐21	   in	   T1D,	   both	  Kenefeck	  et	  al	  and	  Ferreira	  et	  al	  demonstrated	  a	  highly	  significant	  correlation	  between	  the	   frequency	   of	   TFH	   and	   the	   frequency	   of	   IL-­‐21+	   T	   cells	   [67,	   106]	   providing	   strong	  support	   for	  such	  a	  notion.	  However	  since	   IL-­‐21	  can	  also	  be	  produced	  by	  other	  T	  cells,	  
	   18	  
including	  Th17	  cells	   [81,	  82],	  and	   immunosuppressive	  Tr1	  cells[110],	   the	  contribution	  of	  non-­‐TFH	  populations	  cannot	  be	  excluded.	  	  The	  precise	   relationship	  between	  CXCR5+	  T	   cells	   in	   the	   blood	   and	  bona	   fide	  TFH	   cells	  remains	   controversial	   [111].	   	   There	   is	   now	   good	   evidence	   that	   TFH	   can	   become	  circulating	  memory	   cells	   [112-­‐115],	   but	   in	   doing	   so	   they	   downregulate	  many	   of	   their	  characteristic	  TFH	  markers,	  although	  these	  can	  be	  re-­‐gained	  upon	  antigen	  re-­‐encounter	  [116].	   Interestingly,	  one	  study	  showed	  that	  TFH	  that	   lose	  their	  phenotype	  after	  antigen	  deprivation	  retain	  intermediate	  levels	  of	  CXCR5	  [117],	  suggesting	  this	  marker	  may	  offer	  the	  best	   chance	   to	   track	   such	   cells.	   	   The	  presence	  of	  blood-­‐borne	  TFH	   in	   SAP-­‐deficient	  mice	   and	   humans	   suggests	   that	   they	   arise	   prior	   to	   intimate	   T	   cell:B	   cell	   interactions	  within	  the	  GC	  [118]	  and	  while	  it	  is	  technically	  possible	  for	  bona	  fide	  TFH	  to	  exit	  the	  GC	  to	  enter	  the	  circulation,	  this	  appears	  to	  be	  a	  rare	  event	  [119].	  Thus	  the	  CXCR5+	  cells	  in	  the	  circulation	   of	   T1D	   patients	   may	   derive	   from	   pre-­‐TFH	   cells	   that	   have	   bifurcated	   from	  those	   entering	   the	   GC,	   choosing	   instead	   to	   commit	   to	   a	   memory	   pathway.	   The	  generation	  of	  blood	  borne	  TFH-­‐phenotype	  cells	  prior	  to	  the	  development	  of	  GC	  [118]	  is	  consistent	  with	   recent	  data	  highlighting	   that	   the	  homeostasis	  of	   this	  population	   in	  LN	  and	  blood	  can	  be	  strikingly	  different	  [120].	  Despite	  the	  many	  ongoing	  controversies,	  it	  is	  clear	   that	   the	   blood-­‐borne	   CXCR5+	   fraction,	   whilst	   heterogeneous,	   does	   contain	  circulating	   TFH	  memory	   cells	   that	   can	   traffic	   to	   B	   cell	   follicles	   of	   secondary	   lymphoid	  tissues	  and	  contribute	  to	  GC	  reactions	  [120].	  	  
TFH	  and	  autoantibody	  status	  The	   presence	   of	   autoantibodies	   is	   a	   key	   predictor	   of	   diabetes	   development	   in	   at	   risk	  individuals,	   with	   the	   number	   of	   antibodies	   and	   the	   timing	   of	   their	   appearance	   being	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particularly	   telling	   [121,	   122].	   The	   key	   role	   of	   TFH	   in	   class	   switching	   and	   affinity	  maturation	   is	   consistent	   with	   a	   role	   for	   these	   cells	   in	   autoantibody	   production.	  Intriguingly,	   one	   study	   focusing	   on	   newly	   diagnosed	   patients	   identified	   a	   small	  difference	  in	  the	  percentage	  of	  TFH	  cells	  between	  individuals	  that	  were	  either	  positive	  or	  negative	   for	  certain	  autoantibodies.	   	  TFH	  numbers	  appeared	   to	  be	   independent	  of	  GAD	  autoantibody	   status,	   but	   were	   higher	   in	   those	   deemed	   positive	   for	   ZnT8	   or	   IA-­‐2	  autoantibodies	   compared	   with	   autoantibody	   negative	   individuals	   [107].	   The	  relationship	   between	   circulating	   cells	   with	   a	   TFH	   phenotype	   and	   the	   emergence	   of	  autoantibodies	  will	  be	   important	   to	   fully	  elucidate	   in	   future	  studies.	   	  Given	   the	  role	  of	  TFH	  in	  honing	  the	  quality	  of	  the	  B	  cell	  response,	  it	  is	  noteworthy	  that	  autoantibodies	  to	  islet	   antigens	   frequently	   exhibit	   affinity	  maturation	   [123]	   and	   indeed	   the	   presence	   of	  high	   affinity	   autoantibodies	   may	   help	   to	   identify	   those	   individuals	   most	   likely	   to	  progress	   from	  at	  risk	  status	  to	  overt	  diabetes	  [124-­‐126].	   	   It	   is	  possible	  that	  measuring	  peripheral	  blood	  TFH,	  as	  well	  as	  autoantibodies,	  could	  be	  useful	  in	  at	  risk	  individuals	  and	  might	  provide	  additional	  power	  to	  predict	  progression	  to	  overt	  disease.	  	  	  
IL-­‐2	  signaling	  impairs	  TFH	  differentiation	  One	   notable	   aspect	   of	   TFH	   biology	   is	   that	   IL-­‐2	   signaling	   is	   known	   to	   impair	   TFH	  differentiation.	   	  Accordingly,	  signals	  generated	  by	  the	   IL-­‐2	  receptor	  during	  early	  T	  cell	  activation	  can	  influence	  the	  balance	  between	  TFH	  differentiation	  and	  other	  effector	  T	  cell	  fates	  [127,	  128]	  via	  STAT5-­‐dependent	  skewing	  of	  the	  BCL6/BLIMP1	  ratio	  [129].	  	  Elegant	  experiments	   have	   used	  MHC	   class	   II	   tetramers	   to	   home	   in	   on	   antigen	   specific	   T	   cells	  following	   influenza	   infection	   in	   mice	   and	   shown	   that	   IL-­‐2	   administration	   selectively	  decreases	  the	  number	  of	  TFH	  cells	  (CXCR5+PD1+),	  but	  not	  other	  effector	  T	  cells	  (CXCR5-­‐PD1-­‐)	   [130].	   Conversely,	   it	   has	  been	   shown	   that	  under	   conditions	  of	   IL-­‐2	  deprivation,	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Th1	  cells	  can	  acquire	  a	  TFH	  phenotype	  [131].	   	  Thus,	   the	  availability	  of	   IL-­‐2	   in	   the	   local	  environment	  has	  significant	  consequences	  for	  the	  development	  and	  homeostasis	  of	  the	  TFH	  population.	  	  These	  findings	  may	  be	  relevant	  to	  the	  observed	  increase	  in	  TFH	  in	  type	  1	  diabetes,	  since	  multiple	  defects	  in	  the	  IL-­‐2	  signaling	  pathway	  have	  been	  associated	  with	  this	  disease	  setting	  [132-­‐136].	  	  Interestingly	  Kenefeck	  et	  al	  found	  an	  inverse	  relationship	  between	   the	   ability	   of	   T	   cells	   from	   type	   1	   diabetes	   patients	   to	   respond	   to	   IL-­‐2	   and	  propensity	   to	   acquire	   a	   TFH	   phenotype	   in	   vitro	   [106].	   It	   is	   therefore	   possible	   that	  suboptimal	  IL-­‐2	  signaling	  could	  contribute	  to	  increased	  TFH	  differentiation	  in	  T1D.	  	  
Could	  TFH	  be	  responsible	  for	  driving	  disease?	  	  Whether	  TFH	  cells	  are	  directly	  responsible	  for	  autoimmune	  pathology	  is	  hard	  to	  assess	  in	  patients,	  however	  data	  from	  mouse	  models	  does	  provide	  support	  for	  such	  a	  notion.	  	  In	  a	  TCR	   transgenic	   diabetes	   model,	   a	   mutation	   in	   Roquin	   leading	   to	   dysregulated	   TFH	  generation	   dramatically	   accelerated	   diabetes	   development	   [137].	   In	   a	   second	   TCR	  transgenic	   model,	   based	   on	   a	   different	   pancreatic	   antigen	   and	   different	   transgenic	   T	  cells,	   enriching	   for	   T	   cells	   with	   a	   TFH	   phenotype	   increased	   their	   capacity	   to	   cause	  diabetes	  upon	  adoptive	  transfer	  [106].	   	  Anecdotal	  evidence	  also	  links	  the	  TFH	  response	  with	   diabetes	   in	   NOD	   mice:	   the	   spontaneous	   formation	   of	   germinal	   centers	   in	   NOD	  spleen	   has	   been	   documented	   [138]	   and	   germinal	   centers	   have	   even	   been	   detected	  within	  the	  lymphoid	  mass	  infiltrating	  the	  pancreas	  itself	  [139,	  140].	  	  Although	   IL-­‐21	   is	   the	   characteristic	   cytokine	   associated	   with	   TFH	   cells,	   they	   are	   also	  known	  to	  be	  capable	  of	  producing	  other	  cytokines,	  including	  IFN-­‐γ	  which	  could	  explain	  the	  association	  of	   this	  cytokine	  with	  T1D	  [112,	  141].	   	   Indeed	  human	  TFH	   isolated	   from	  lymph	   nodes	   of	   chronically	   HIV-­‐infected	   subjects	   were	   shown	   to	   be	   capable	   of	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substantial	  co-­‐production	  of	  cytokines,	   including	  IL-­‐21,	  TNF-­‐α	  and	  IFN-­‐γ [142].	  Several	  studies	  have	  implicated	  persistent	  antigen	  presentation	  in	  TFH	  differentiation	  [117,	  143],	  a	  notion	   that	  might	   fit	  with	   the	   inability	  of	   self	   antigens	   to	  be	   cleared	   in	   autoimmune	  settings.	   	   Interestingly,	   TFH	   differentiation	   is	   subject	   to	   regulation	   by	   a	   number	   of	  pathways	  that	  are	  genetically	  linked	  to	  autoimmunity,	  including	  the	  CD28/CTLA-­‐4	  axis	  [144-­‐150],	  IL-­‐2	  [127-­‐130]	  and	  the	  LYP	  tyrosine	  phosphatase	  encoded	  by	  PTPN22	  [151].	  The	   link	   between	   these	   loci	   and	   disease	   initiation	   is	   complex,	   but	   modulation	   of	   TFH	  differentiation	   adds	   an	   additional	   consideration	   to	   the	   other	   known	   roles	   of	   the	  candidate	  genes	  in	  these	  locations.	  	  
Concluding	  Comments	  The	   complexities	   of	   CD4	   T	   cell	   differentiation	   are	   still	   emerging	   but	   we	   have	   clearly	  moved	  beyond	  the	  era	  of	  a	  simple	  Th1/Th2	  dichotomy.	  	  Recent	  data	  suggest	  that	  early	  T	  cell	   differentiation	   is	   likely	   to	   be	   even	  more	   diverse	   than	  was	   previously	   appreciated	  [152],	  with	  a	  broad	  selection	  of	  functional	  phenotypes	  being	  generated,	  the	  most	  useful	  of	  which	   are	   then	   selectively	   expanded.	   	  Moreover,	   intermediate	  differentiation	   states	  exist,	   including	   a	   TFH-­‐like	   transitional	   stage	   shared	   by	   TFH	   and	   Th1	   cells	   [153],	   and	  phenotypic	   conversions	   are	   possible,	   such	   as	   the	   switch	   from	   Th1	   to	   TFH	   under	  conditions	  of	  limiting	  IL-­‐2	  [131].	  	  These	  developments	  argue	  for	  a	  more	  nuanced	  view	  of	  T	  cell	  differentiation	  in	  type	  1	  diabetes	  that	  does	  not	  focus	  solely	  on	  Th1	  cells	  but	  also	  encompasses	  the	  possible	  involvement	  of	  IL-­‐21-­‐producing	  T	  cells	  such	  as	  TFH,	  as	  well	  as	  T	  cells	  co-­‐producing	  IFN-­‐γ	  and	  IL-­‐17.	  	  	  The	  demonstration	  of	  an	  augmented	  TFH	  population	  in	  type	  1	  diabetes	  [67,	  106,	  107]	  is	  in	   line	   with	   a	   growing	   appreciation	   that	   TFH	   differentiation	   is	   a	   feature	   of	   several	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autoimmune	   diseases	   ([154]	   and	   reviewed	   in	   [155]).	   Increasingly	   refined	   genetic	  analysis	  suggests	  that	  T1D	  may	  be	  more	  similar	  to	  other	  autoantibody-­‐positive	  diseases,	  such	  as	  juvenile	  idiopathic	  arthritis	  and	  rheumatoid	  arthritis,	  than	  to	  conditions	  lacking	  characteristic	  autoantibodies,	  such	  as	  ulcerative	  colitis	  and	  Crohn’s	  disease	  [156].	  This	  is	  clearly	   consistent	   with	   potential	   involvement	   of	   TFH	   cells	   in	   the	   underlying	  immunological	  processes.	  	  	  	  TFH	  cell	  numbers	   in	   the	  peripheral	  blood	  are	   increasingly	  being	   linked	  with	  protective	  antiviral	   immunity	   [157-­‐159].	   This	   is	   interesting	   given	   the	   longstanding	   debate	  regarding	   the	  putative	   contribution	   of	   viral	   infection	   to	   diabetes	   initiation	   [160,	   161].	  	  One	   could	   envisage	   that	   evolutionary	   selection	   for	   characteristics	   that	   confer	   an	  advantage	   in	   infectious	   settings	   might	   have	   also	   influenced	   susceptibility	   to	  autoimmunity	  in	  parallel.	  	  One	  potential	  benefit	  of	  broadening	  our	  perception	  of	  T	  cell	  differentiation	   in	  diabetes	  beyond	  the	  simple	  Th1	  paradigm	  is	  the	  prospect	  of	  identifying	  new	  disease	  biomarkers	  (Fig.	  4).	  Exploration	  of	  CXCR5,	  or	  other	  markers	  of	  circulating	  TFH-­‐like	  cells,	  may	  present	  new	  opportunities	   for	  assessing	  diabetes	  risk,	   tracking	  disease	  progression	  or	  gauging	  response	   to	   therapeutic	   interventions.	   We	   envisage	   that	   an	   increasingly	   refined	  understanding	  of	  the	  CD4	  T	  cell	  population	  in	  type	  1	  diabetes	  will	  help	  us	  to	  monitor	  the	  autoimmune	  response	  and	  ultimately	  deploy	  effective	  immunomodulatory	  strategies	  in	  this	  disease	  setting.	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Figure	  Legends	  	  
Fig.	  1.	  The	  original	  Th1	  /	  Th2	  paradigm	  in	  Type	  1	  Diabetes.	  Type	  1	  diabetes	  has	  traditionally	  been	  viewed	  as	  a	  Th1-­‐mediated	  pathology,	  with	  Th2	  cells	  playing	  a	  protective	  role.	  	  The	  characteristic	  transcription	  factors	  and	  a	  selection	  of	  surface	  markers	  associated	  with	  Th1	  cells	  or	  Th2	  cells	  is	  shown.	  	  
Fig.	  2.	  T	  cell	  cytokine	  production	  in	  type	  1	  diabetes.	  	  (A)	  Many	  studies	  have	  assessed	  IFN-­‐γ	  in	  isolation	  as	  a	  measure	  of	  the	  Th1	  response.	  (B)	  Some	  studies	  suggest	  T	  cells	  co-­‐expressing	  IFN-­‐ γ	  and	  IL-­‐17	  may	  be	  expanded	  in	  people	  with	  type	  1	  diabetes	  (refs	  60,	  71)	  (C)	  IL-­‐21	  producing	  T	  cells	  in	  the	  pancreas	  in	  mouse	  models	  of	  diabetes	  have	  been	  shown	  to	  co-­‐express	  TNF-­‐α	  and	  IFN-­‐γ	  (ref	  106).	  IL-­‐21-­‐producing	  T	  cells	  are	  elevated	  in	  T1D	  patients	  (refs	  106,	  67),	  and	  can	  co-­‐express	  TNF-­‐α	  and	  IFN-­‐γ	  (ref	  106).	  	  
Fig.	  3.	  Potential	  effects	  of	  IL-­‐21	  on	  immune	  cells	  in	  type	  1	  diabetes.	  IL-­‐21	  is	  a	  highly	  pleiotropic	  cytokine	  and	  could	  potentially	  act	  on	  several	  different	  cell	  types	  in	  the	  context	  of	  type	  1	  diabetes	  development	  (see	  manuscript	  text	  for	  references).	  	  	  
Fig.	  4.	  Potential	  utility	  of	  biomarkers	  arising	  from	  a	  better	  understanding	  of	  the	  T	  
cell	  phenotype	  in	  T1D.	  Surface	  markers	  and/or	  secreted	  products	  from	  CD4	  T	  cells	  can	  potentially	  be	  used	  to	  gauge	  the	  risk	  of	  T1D	  development,	  in	  conjunction	  with	  established	  risk	  indicators.	  They	  may	  also	  be	  used	  to	  refine	  patient	  stratification,	  perhaps	  selecting	  groups	  that	  might	  be	  predicted	  to	  benefit	  from	  a	  particular	  immune	  intervention.	  	  Longitudinal	  studies	  may	  reveal	  whether	  particular	  markers	  can	  be	  used	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to	  stage	  the	  disease	  process.	  Phenotypic	  markers	  may	  also	  be	  of	  utility	  in	  assessing	  the	  efficacy	  of	  therapeutic	  interventions,	  perhaps	  in	  combination	  with	  tetramer	  technology.	  	  
Table	  1.	  IL-­‐21	  production	  at	  the	  site	  of	  the	  autoimmune	  attack	  in	  mouse	  models	  of	  
type	  1	  diabetes.	  Table	  showing	  data	  relating	  to	  IL-­‐21	  expression	  in	  mouse	  models	  of	  diabetes.	  	  
Table	  2.	  Link	  between	  TFH	  differentiation	  and	  autoimmune	  diabetes.	  Table	  collating	  some	  of	  the	  evidence	  that	  suggests	  TFH	  differentiation	  may	  be	  a	  feature	  of	  autoimmune	  diabetes	  in	  mice	  and	  humans.	  	  	  	  
Publication 
 
Findings Mouse Model 
Clough et al. 
(ref 77) 
 
Increased IL-21 mRNA in pancreatic lymph 
nodes of diabetic compared with non-diabetic 
mice.  
 
DO11 x rip-OVA 
 
Sutherland et al. 
(ref 78) 
 
Increased IL-21 mRNA were in the pancreas 
of diabetic compared with non-diabetic mice. 
 
NOD 
McGuire et al. 
(ref 84) 
 
Enrichment of IL-21-producing T cells within 
the pancreas compared with peripheral 
lymphoid organs. Fewer IL-21+ T cells were 
observed in the pancreas of NOD mice 
bearing the B6 Idd3 region. 
 
NOD 
Kenefeck et al. 
(ref 106) 
 
Enrichment of IL-21-producing T cells within 
the pancreas compared with peripheral 
lymphoid organs. The IL-21-producing T cells 
co-express TNF-α and IFN-γ but not IL-17. 
 
DO11 x rip-OVA 
 
 
Table 1. IL-21 production at the site of the autoimmune attack in mouse models 





Increase in TFH genes in 
microarray of T cells responding 
to islet antigen in the pancreatic 
LN (ref 106) 
 
Increased production of IL-21 after ex vivo 
stimulation of memory T cells from T1D patients 
compared with matched controls (ref 106, 67) 
Increased TFH differentiation 
due to roquin mutation 
exacerbates diabetes (ref 137) 
 
Increased IL-21 mRNA in memory T cells from new 
onset T1D patients compared with matched 
controls (ref 107) 
CXCR5-enriched T cells 
preferentially induce diabetes 
upon adoptive transfer (ref 106) 
 
Increased numbers of cells with a TFH phenotype in 
blood of T1D patients compared with controls (ref 
106, 67, 107). Correlation between frequency of 
TFH and IL-21+ T cells (ref 106, 67) 
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